IBJNews

2010 WOMAN OF INFLUENCE: Annette W. Cyr

Back to TopCommentsE-mailPrintBookmark and Share

Senior Vice President, Global Human Resources, Brightpoint Inc.

Sphere of Influence: Saying that Cyr has lots of irons in the fire is a supreme understatement. Since joining the global communications technology firm in 2003, Brightpoint’s senior vice president, global human resources, has established a world-spanning HR team and rationalized the company’s practices across timelines, continents and cultures.
 

Cyr (IBJ Photo/ Perry Reichanadter)

Annette W. Cyr, 47, has had her hands full at Brightpoint since the day she signed on. During her tenure as the company’s senior vice president, global human resources, she has coached and mentored employees around the globe, learning about their diverse cultures and special challenges. That’s a tall order, considering that the company conducts business in 25 countries and employs some 2,700 staffers worldwide.

Throughout the firm’s hectic growth she’s guided the company to consistent, global HR policies that support Brightpoint’s strategy and operational plans. Cyr says the key is to identify practices and processes that have to be handled consistently everywhere, but also to allow local managers to customize things that are best tackled on-site. That calls for extensive discussions and involvement by a wide range of factions to insure global “buy-in” with new systems.

“It’s a delicate balance,” Cyr said. “We strive to ensure that no matter where our team members work, they feel part of the global Brightpoint team.”

Over the last few years Cyr has focused attention on leadership development and performance management. Committed to personal communication with her global HR team, she conducts monthly calls in which executives can share their thoughts on the business in general and HR in particular.

Such tactics have won her a “seat at the table” for big decisions.

“I am proudest of the engagement of HR by our key corporate and regional executives in all areas of decision making,” Cyr said. “As an HR professional, it is very satisfying to work with colleagues who understand that our people define us and must be considered in critical decisions.”

She doesn’t expect the hectic schedule she’s dealt with for the past few years to let up anytime soon. It’s part and parcel of working for a fast-growing company. “The pace of change, both in our industry and generally in the business environment, will continue to challenge everyone,” Cyr said. “The amount of data to review and understand is increasing so rapidly. We have to better prioritize than in the past.”

Cyr likes to spend her downtime in Montana, where she and her husband, Bob, lived before moving to Indianapolis. They’re both big fans of skiing and summer hiking. They have two grown daughters, Michele and Wendy.

Click here to return to the Women of Influence landing page.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. So, Pence wants the federal government to ignore the 2008 law that allows children from these countries to argue for asylum in front of a judge. How did this guy become governor? And how is that we'll soon be subjected to repeatedly seeing him on TV being taken seriously as a presidential candidate? Am I in Bizzaro-U.S.A.?

  2. "And the most rigorous studies of one-year preschool programs have shown short-term benefits that fade out in a few years or no benefits at all." So we are going down a path that seems to have proven not to work very well. Right intention, wrong approach?

  3. Well for Dunkin Donuts it might say that even a highly popular outlet can't make a poorly sited location work. That little strip has seen near constant churn for years.

  4. Years ago, the Pharmaceutical and Medical Device companies shifted their research investment away from Medical Institutions to focus more on private research centers, primarily because of medical institution inefficiencies in initiating clinical studies and their inability/commitment to enroll the needed number of patients in these studies. The protracted timelines of the medical institutions were prompting significant delays in the availability of new drug and medical device entities for patients and relatedly, higher R and D expenditures to the commercial industry because of these delays. While the above stated IU Health "ratio is about $2.50 in federal funding for every $1 in industry funding", the available funding is REVERSED as commercial R and D (primarily Phase I-IV clinical work)runs $2.50 to $1 for available federal funding ($76.8B to $30.9B in 2011). The above article significatly understated the available R and D funding from industry......see the Pharma and Medical Device industry websites. Clearly, if medical institutions like IU Health wish to attract more commercial studies, they will need to become more competitive with private clinical sites in their ability to be more efficient and in their commitment to meet study enrollment goals on time. Lastly, to the reference to the above Washington Post article headlined “As drug industry’s influence over research grows, so does the potential for bias", lacks some credibility as both FDA and Institutional Institutional Review Boards must approve the high proportion of these studies before studies are started. This means that both study safety and science must be approved by both entities.

  5. ChIeF and all the other critics – better is better no matter what. Get over it; they are doing better despite you ?

ADVERTISEMENT